|Therapeutic Class:||Centrally acting antihypertensive drugs (central sympatholytic)|
|Manufacturer:||Cosmic Pharma Limited|
|Last Updated:||2020-11-21 18:15:00|
Aldomet Tablet contains Methyldopa. Aldomet uses:
Aldomet Tablet is indicated in Hypertension
Aldomet Tablet contains Methyldopa 250 mg. Aldomet doses:
Initiation of Therapy: The usual starting dosage of Aldomet Tablet is 250 mg two or three times a day in the first 48 hours. The daily dosage then may be increased or decreased, preferably at intervals of not less than two days, until an adequate response is achieved. To minimize the sedation, start dosage increases in the evening. When Aldomet Tablet is given to patients on other antihypertensives, the dose of these agents may need to be adjusted to effect a smooth transition. When Aldomet Tablet is given with antihypertensives other than thiazides, the initial dosage of Aldomet Tablet should be limited to 500 mg daily in divided doses; when Aldomet Tablet is added to a thiazide, the dosage of thiazide need not to be changed.
Maintenance Therapy: The usual daily dosage of Aldomet Tablet is 500 mg to 2 g in two to four doses. Although occasional patients have responded to higher doses, the maximum recommended daily dosage is 3 gm. Occasionally tolerance may occur, usually between the second and third month of therapy. Adding a diuretic or increasing the dosage of Aldomet Tablet frequently will restore effective control of blood pressure. A thiazide may be added at any time during Aldomet Tablet therapy and is recommended if therapy has not been started with a thiazide or if effective control of blood pressure cannot be maintained on 2 gm of Aldomet Tablet daily. Aldomet Tablet is largely excreted by the kidney and patients with impaired renal function may respond to smaller doses. Syncope in older patients may be related to an increased sensitivity and advanced arteriosclerotic vascular disease. This may be avoided by lower doses.
Initial dosage is based on 10 mg/kg of body weight daily in two to four doses. The daily dosage then is increased or decreased until an adequate response is achieved. The maximum dosage is 65 mg/kg or 3 gm daily, whichever is less.
Sedation, usually transient, may occur during the initial period of therapy or whenever the dose is increased. Headache, asthenia, or weakness may be noted as early and transient symptoms. The following systemic side effects may rarely occurs with the use of Aldomet Tablet - angina pectoris, congestive heart failure, orthostatic hypotension, edema or weight gain, bradycardia, pancreatitis, colitis, vomiting, diarrhea, nausea, constipation, dryness of mouth, hyperprolactinemia, bone marrow depression, leukopenia, granulocytopenia, thrombocytopenia, hemolytic anemia; rheumatoid factor, hepatitis, jaundice, myocarditis, pericarditis, vasculitis, eosinophilia, parkinsonism, bell's palsy, nightmares and reversible mild psychoses or depression, dizziness, lightheadedness, paresthesias, arthralgia, myalgia, nasal stuffiness, rash, amenorrhea, gynecomastia, lactation, impotence. However, significant adverse effects due to Aldomet Tablet have been infrequent and this agent usually is well tolerated.
Although the mechanism of action has yet to be conclusively demonstrated, the resultant hypotensive effect is most likely due to the drug's action on the CNS. Aldomet Tablet is converted into the metabolite, alpha-methylnorepinephrine, in the CNS, where it stimulates the central inhibitory alpha-adrenergic receptors, leading to a reduction in sympathetic tone, total peripheral resistance, and blood pressure. Reduction in plasma renin activity, as well as the inhibition of both central and peripheral norepinephrine and serotonine production may also contribute to the drug's antihypertensive effect, although this is not a major mechanism of action. This is done through the inhibition of the decarboxylation of dihydroxyphenylalanine (dopa)- the precursor of norepinephrine, 5-hydroxytryptophan (5-HTP), serotonin (in the CNS) and in most peripheral tissues.
Patient with history of haemolytic anaemia, liver disease or depression; parkinsonism, hepatic porphyria. Not intended for the treatment of phaeochromocytoma. Renal or hepatic impairment. Childn, elderly. Pregnancy and lactation.
When Aldomet Tablet is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. Patients may require reduced doses of anesthetics when on Aldomet Tablet. When Aldomet Tablet and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity. Coadministration of Aldomet Tablet with ferrous sulfate or ferrous gluconate is not recommended.
Pregnancy Category B. Aldomet Tablet appears in breast milk. Therefore, caution should be exercised when Aldomet Tablet is given to a nursing woman.
Aldomet Tablet is contraindicated in patients with:
Pediatric Use: There are no well-controlled clinical trials in pediatric patients. Information on dosing in pediatric patients is supported by evidence from published literature regarding the treatment of hypertension in pediatric patients.
Acute overdosage may produce acute hypotension with other responses attributable to brain and gastrointestinal malfunction (excessive sedation, weakness, bradycardia, dizziness, lightheadedness, constipation, distention, flatus, diarrhea, nausea, vomiting). In the event of overdosage, symptomatic and supportive measures should be employed. When ingestion is recent, gastric lavage or emesis may reduce absorption. When ingestion has been earlier, infusions may be helpful to promote urinary excretion.
Aldomet Tablet price in Bangladesh 0.00